Reply to: Adjuvant Treatment Options and Modalities in Pancreatic Adenocarcinoma: Insights From ESPAC4

Daniel H. Palmer

Liverpool ECMC, University of Liverpool and Clatterbridge Cancer Centre, Liverpool, United Kingdom

Richard J. Jackson

Daniel H. Palmer, PhD and Richard J. Jackson, PhD, University of Liverpool, Liverpool, United Kingdom; Christoph Springfeld, MD, Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Thilo Hackert, MD, Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and Christoph W. Michalski, MD and John P. Neoptolemos, MD, Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany

Christoph Springfeld

Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg, Germany

Thilo Hackert

Christoph W. Michalski

John P. Neoptolemos

Daniel H. Palmer, PhD and Richard J. Jackson, PhD, University of Liverpool, Liverpool, United Kingdom; Christoph Springfeld, MD, Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Thilo Hackert, MD, Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and Christoph W. Michalski, MD and John P. Neoptolemos, MD, Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany